^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Excerpt:
Eligible patients had tumoral phosphatidylinositol-4,5-biphosphate 3 kinase catalytic subunit alpha (PIK3CA) alterations by next-generation sequencing and disease progression after at least one line of platinum-based therapy. Patients received 4-mg taselisib orally daily...Median progression-free survival and overall survival in the PAP group were 2.9 months (95% CI: 1.8-4.0 mo) and 5.9 months (95% CI: 4.2-7.8 mo), respectively. These numbers were nearly the same in the FEP.
DOI:
10.1016/j.jtho.2019.05.029
